A comprehensive review published in the journal JAMA Otolaryngology—Head and Neck Surgery on September 3, 2025, highlights emerging evidence that GLP-1 receptor agonists—commonly prescribed for weight loss—may significantly reduce the severity of obstructive sleep apnea (OSA) in individuals with obesity.
The study, conducted by researchers at the University of Pittsburgh Medical Center, analyzed clinical trials and medical literature from 2016 to 2025, including the SCALE Sleep Apnea trial, the first randomized clinical trial of a GLP-1 drug in OSA patients. Findings indicate that weight reduction—a primary modifiable risk factor for OSA—plays a key role in improving symptoms. Specifically, the review noted that a 10% increase in body weight is associated with a 32% rise in the apnea-hypopnea index (AHI), a measure of OSA severity.
In clinical trials reviewed, participants taking tirzepatide (sold as Zepbound or Mounjaro) experienced 20 to 24 fewer breathing interruptions per hour compared to placebo users, with nearly half achieving remission of OSA symptoms. The improvement is attributed to fat loss in the tongue and throat, which helps keep the airway open during sleep. The U.S. Food and Drug Administration (FDA) approved Zepbound for moderate to severe OSA in adults with obesity in 2024, marking a shift toward medication-based treatment options.
Obesity’s Role in Sleep Apnea
OSA affects nearly 1 billion adults worldwide and is strongly linked to cardiovascular disease, stroke, and increased mortality. Obesity—defined as a body mass index (BMI) of 30 or higher—is present in 60 to 70% of OSA cases, making it the primary modifiable risk factor. The University of Pittsburgh researchers emphasized that weight loss interventions, including GLP-1 drugs, could address this underlying cause. However, the study notes that CPAP machines—the standard OSA treatment—remain more effective at reducing breathing interruptions than GLP-1 medications alone.
Potential and Limitations
While the findings are promising, experts caution that GLP-1 drugs are best positioned as a complementary therapy alongside existing treatments like CPAP. The review suggests that combining weight-loss medications with traditional OSA therapies could provide greater overall benefit than either approach alone. Researchers also highlight the need for longer-term studies to assess sustained effects and potential side effects of prolonged GLP-1 use.
Next Steps for Patients and Providers
The study underscores the importance of personalized treatment plans for OSA, particularly for patients with obesity. Healthcare providers may increasingly consider GLP-1 drugs as part of a broader strategy to manage OSA, alongside lifestyle modifications and established therapies. The FDA’s approval of Zepbound for OSA in 2024 reflects growing recognition of these medications’ potential role in treatment.
For now, CPAP machines remain the gold standard, but the research suggests that GLP-1 drugs could offer a valuable adjunct therapy, particularly for patients struggling with obesity-related OSA.